• +33 (0)3 81 41 38 38
  • orders [at] medixbiochemica [dot] com

Search for products

Human IL-1β ELISA Kit

Product Specifications

Catalogue N°
850.006.048 - 1 x 48 Discovery (pre-coated)
850.006.096 - 1 x 96 (pre-coated)
850.006.192 - 2 x 96 (pre-coated)
Assay Range
15.6 pg/ml - 500 pg/ml
Sensitivity
6.5 pg/ml
Target species
Human
Specificity
Recognizes both natural (pro and mature) and recombinant human IL-1b
Incubation
3h45
Sample Type
Serum, Plasma, Cell culture supernatant
Sample Size
100 µl
Cross Reaction
No cross reactivity with other human cytokines
Kit Content
Diaclone ELISA Kits include pre-coated strip plates, biotinylated secondary antibody, standards, controls (where applicable), buffers, streptavidin-HRP, TMB, stop reagents and a detailed procedure.
Synonym
IL-1b
IL-1beta
IL-1b ELISA Kit
Example of Human IL-1b Standard Curve

References

  • Barska,K. et al.,PLoS One, 2017; 12(7): e0181533. - Pubmed link
  • Beyth S. et al., Blood, 2005; 105(5): 2214 - 2219 - Pubmed link
  • Buenestado, A. et al., J Parenter Enteral Nutr.,2006;30(4):286-96 - Pubmed link
  • Castroflorio, T. et al., Angle Orthod.,2016;DOI:10.2319/022416-159.1 - Pubmed link
  • Chavushyan, A. et al., Schizophr Res Treatment, 2013: 125264 - Pubmed link
  • Corvaisier, M. et al., PLoS Biol.,2012;10(9): e1001395 - Pubmed link
  • Cunin, P. et al., J. Immunol.,2011;186(7): 4175-4182. - Pubmed link
  • Cutolo M. et al., Ann. Rheum. Dis, 2005; 65(6): 728-35 - Pubmed link
  • Cutolo, M. et al., Arthritis Res Ther.,2009;11(6): R176 - Pubmed link
  • Diaw, M. et al., Diabetes Care,2015; 38(11): 2120-2127 - Pubmed link
  • Eilertsen, G. O. et al.,Lupus,2011;20(6):607-613. - Pubmed link
  • Fernandez-Lizarbe, S. et al., J. Immunol.,2009; 183(7): 4733-4744. - Pubmed link
  • Fornander, L. et al., PLoS One,2013; 8(12): e83089 - Pubmed link
  • Gomez-Tortosa, E. et al., Arch Neurol.,2003;60(9):1218-22 - Pubmed link
  • Kerr J. et al., J. Gen. Virol., 2001; 82(Pt 12): 3011-3019 - Pubmed link
  • Kurowski, M. et al.,Arch Med Sci. 2018 Jan;14(1):60-68. - Pubmed link
  • Kwon K.Y. et al., J. Korean Med. Sci., 2001; 16(6): 774 - 780 - Pubmed link
  • Lapinet J.A. et al., Infect Immun.,2000; 68(12):6917-23 - Pubmed link
  • Lewis, S. et al., Respir Res.,2009; 10: 44 - Pubmed link
  • Lietzen, N. et al.,PLoS Pathog.,2011;7(5):e1001340 - Pubmed link
  • Lu, C. et al., Lupus, 2015;24(1):18-24 - Pubmed link
  • Markiewicz, L. et al.,Biomed Res Int.,2015; 2015: 812503 - Pubmed link
  • Miot, C. et al., Gut,2014: gutjnl-2013-306604 - Pubmed link
  • Mochel, F. et al., PLoS One,2007; 2(7): e647. - Pubmed link
  • Mohamed, H. S. and M. M. Meguid, Saudi J Anaesth.,2017;11(1): 9-14. - Pubmed link
  • Mokhtare, M. et al.,Middle East J Dig Dis. 2017 Oct;9(4):228-234. - Pubmed link
  • Montero M.T. et al., J. Immunol., 2004; 173(8): 4936 - 4944 - Pubmed link
  • Nagao, Y. et al., Malar J.,2008; 7: 113. - Pubmed link
  • Ohman, T. et al., J. Immunol.,2014;192(12):5952-5962 - Pubmed link
  • Paduch, R. and A. Wozniak J Ophthalmic Vis Res.,2015; 10(3): 229-37 - Pubmed link
  • Paduch, R. et al.,Balkan Med J.,2014;31(1): 29-36 - Pubmed link
  • Rai, G. et al.,Ann Lab Med., 2018 Mar;38(2):125-131 - Pubmed link
  • Rajbhoj, P. H. et al.,J Clin Diagn Res.,2015; 9(2): CC01-5 - Pubmed link
  • Shadman, Z. et al., J Diabetes Metab Disord.,2013; 12(1): 42 - Pubmed link
  • Suzuki, N. et al., Tob Induc Dis.,2016; 14: 20. - Pubmed link
  • Tantibhedhyangkul, W. et al.,PLoS Negl Trop Dis.,2011; 5(5): e1028. - Pubmed link
  • Tuttolomondo, A. et al.,PLoS One,2016; 11(12): e0165443 - Pubmed link
  • Zhou, C. et al., J Neuroinflammation,2015; 12(1): 200 - Pubmed link
  • Loo, W. T. et al.,J Transl Med.,2012; 10 Suppl 1: S8 - Pubmed link
  • Bułdak, L. et al., Exp Ther Med. 2019 Apr;17(4):2861-2869 - Pubmed link
  • Kordulewska, N.K. et al., Int J Mol Sci. 2019 Jan; 20(1): 186 - Pubmed link
  • Molteni, M. et al.,Toxins (Basel). 2018 Jul 16;10(7). pii: E290 - Pubmed link
  • Tryniszewski, W. et al., Acta Endocrinol (Buchar). 2018 Oct-Dec;14(4):439-446. - Pubmed link
  • Zakerkish, M. et al., Sci Rep. 2019 May 13;9(1):7289 - Pubmed link
  • Żebrowska, A. et al., Biomed Res Int. 2019 Sep 22;2019:7315714. - Pubmed link
  • KÖŞger, F. et al., Noro Psikiyatr Ars. 2020 Dec; 57(4): 303–307. - Pubmed link
  • Zutshi, D. V. et al., Indian Heart J. 2020 Sep-Oct; 72(5): 389–393. - Pubmed link
  • Tomaszewska, K. et al., Oxid Med Cell Longev. 2020; 2020: 5693572. - Pubmed link
  • Aranda-Valera, I. C. et al., Pediatr Rheumatol Online J. 2020; 18: 59. - Pubmed link
  • Rodriguez-Martin, N. M. et al., Biomolecules. 2020 May; 10(5): 803. - Pubmed link
  • Zbakh, H. et al., Mar Drugs. 2020 Apr; 18(4): 207. - Pubmed link
  • Rezaeitalab, F. et al., Curr J Neurol. 2020 Apr 3; 19(2): 47–52 - Pubmed link
  • Puig, N. et al., Cells. 2020 Mar; 9(3): 583. - Pubmed link
  • Gutiérrez, M. et al., Mar Drugs. 2020 Feb; 18(2): 84. - Pubmed link
  • Ganie, M. A. et al., Front Endocrinol (Lausanne) 2019; 10: 699. - Pubmed link
  • Castellano, J. M. et al., Biomolecules. 2019 Nov; 9(11): 683. - Pubmed link
  • Motamed, S. et al., Matern Child Nutr. 2019 Oct; 15(4): e12867. - Pubmed link
  • Tuettenberg, A. et al., Exp Dermatol. 2007 Mar; 16(3): 171–178. - Pubmed link
  • Swift, T. et al., R Soc Open Sci. 2021 Jan; 8(1): 201655 - Pubmed link
  • Kumar, R. et al., Asian J Transfus Sci. 2021 Jul-Dec; 15(2): 125–132. - Pubmed link
  • Kusmiati, T. et al., Ann Med Surg (Lond) 2021 Oct; 70: 102862. - Pubmed link
  • Nobari, H. et al., J Int Soc Sports Nutr. 2021; 18: 42. - Pubmed link
  • Prat, M. et al., Cancers (Basel) 2021 Apr; 13(8): 1845. - Pubmed link
  • Sajna, H.R. et al., J Int Soc Prev Community Dent. 2021 Jul-Aug; 11(4): 421–427. - Pubmed link
  • Shyam Prasad Shetty B. et al., Toxics. 2021 Apr; 9(4): 72. - Pubmed link
  • Claro-Cala, C.M. et al., Foods. 2022 Aug; 11(15): 2366. - Pubmed link
  • Angelova, G. et al., J Fungi (Basel) 2022 Jul; 8(7): 738. - Pubmed link
  • Kryczyk-Kozioł, J. et al., Nutrients. 2022 Jul; 14(14): 2869. - Pubmed link
  • Colarusso, C. et al., Front Immunol. 2022; 13: 934264. - Pubmed link
  • Kocak-Oztug, N.A. et al., Biomed Res Int. 2022; 2022: 2603287. - Pubmed link
  • Zhong, C. et al., Aging (Albany NY) 2022 Apr 15; 14(7): 3313–3324. - Pubmed link
  • Vlassopoulou, M. et al., J Fungi (Basel) 2022 Apr; 8(4): 329. - Pubmed link
  • Ogłodek, E., Brain Sci. 2022 Mar 14;12(3):387.  - Pubmed link
  • Villanueva-Lazo, A. et al., Foods. 2022 Mar; 11(5): 623. - Pubmed link
  • Porpora, M. et al., Int J Mol Sci. 2022 Feb; 23(4): 1973. - Pubmed link

BACKGROUND

Interleukin-1 Beta (IL-1b) is a member of the interleukin-1 family. This family consists of three structures related polypeptides. The first two are IL-1a and IL-1b, each of which has a broad spectrum of both beneficial and harmful biologic actions, and the third is IL-1-receptor antagonist, which inhibits the activities of interleukin-1.

IL-1 a and b present approximately 25% homology at the amino acid level, but the difference is in their tri dimensional structure. Two distinct receptor types have been isolated, that bind both forms.IL-1b are synthesized as a larger precursor, with a molecular weight 31kda. The molecular weight of the mature form is 17.5kDa.Unlike IL1a, the IL-1b precursor show a little or no biological activity in comparison to the mature form.

IL-1 is primarily an inflammatory cytokine. It belongs to a groups of cytokines with overlapping biologic properties (TNFa and IL-6). IL-1, TNF and IL-6 share the ability to stimulate T and B lymphocytes, increase cell proliferation, and initiate or suppress gene expression for several proteins. It exerts their effects by binding to specific receptors.

IL-1 (a and b) have similar biological properties, among them, the ability to induce fever, sleep, anorexia and hypotension. IL-1 stimulates the release of pituitary hormones, increases the synthesis of collagenases, resulting in the destruction of cartilage, and stimulates the production of prostaglandins, leading to decrease in the pain threshold. In addition IL-1 has some host-defense properties. However, whereas IL-1b is a secreted cytokine, IL-1a is predominantly a cell-associated cytokine.

IL-1 has also been implicated in the destruction of beta cells of the islets of Langerhans, the growth of myelogenous leukaemia cells, and the development of atherosclerotic plaques. It is described in several diseases : sepsis syndrome, rheumatoid arthritis, inflammatory Bowel disease, acute and chronic myelogenous leukaemia, insulino-dependant diabetes mellitus, artherosclerosis.

Version 25 - 09.22

For research use only

Documents

print Request more information

For any order, the purchaser acknowledges having read and accepted the terms and conditions described on the Diaclone website.

Formats Available

850.006.048 1 x 48 Discovery (pre-coated)
850.006.096 1 x 96 (pre-coated)
850.006.192 2 x 96 (pre-coated)

Ordering options

Place an order
by phone: +33 (0)3 81 41 38 38
or by email: info [at] diaclone [dot] com ( Subject: Diaclone's order, Body: Human IL-1β ELISA Kit 850.006.048 - 1 x 48 Discovery (pre-coated) 850.006.096 - 1 x 96 (pre-coated) 850.006.192 - 2 x 96 (pre-coated) )

Please contact us to discuss bulk orders